Archive for the 'Outsourcing' Category

Is the US Facing a Pharmaceutical Manufacturing Gap?

Patricia Van Arnum PharmTech editor Last week, FDA Commissioner Margaret A. Hamburg testified before the House Committee on Energy and Commerce, Subcommittee on Health to outline the agency’s case for supporting the fifth authorization of the Prescription Drug User Fee Act (PDUFA), also known as PDUFA V. In addition to offering her support for PDUFA V, Hamburg also discussed renewal of legislation for promoting pediatric drug testing, the need of FDA to invest in science and innovation, and the agency’s efforts in confronting the continual challenges of globalization. In tackling globalization, a basic question arises: does the United States face a pharmaceutical manufacturing disconnect? Read more »

Bring Manufacturing Back, Orders Obama

Angie Drakulich PharmTech editorLast night, President Obama issued a call to action for manufacturers that involves reducing outsourcing. His 2012 State of the Union address provided a blueprint for rebuilding America’s economy—and a large component is of that plan is to bring manufacturing back to the US. “Tonight, my message to business leaders is simple: Ask yourselves what you can do to bring jobs back to your country, and your country will do everything we can to help you succeed,” he said. Read more »

Pharma 2012: Hard Times Before the Harvest

Guest blog by William Looney, editorial director of Pharmaceutical Executive

2012 will be a transition year for pharma, one of the most important in the industry’s history of product cycles that spin from plenty to penury. On the positive side, the fires of drug discovery are finally being stoked by a growing understanding of how genomics shape the biology of disease. This is leading to promising new treatments that target critical areas of unmet medical need while also increasing the efficacy of interventions geared to the individual patient. Evidence that these next-generation innovations can advance the science while improving outcomes will hopefully lead to ready acceptance in the market, despite the growing leverage of a much more skeptical and discerning customer base. Read more »

Thirty-Five Years in the Pharmaceutical Sciences and Counting

Patricia Van Arnum PharmTech editor A new year is often reason to reflect on what has occurred and to consider what the future may hold. And for 2012, Pharmaceutical Technology is doing just that. Next year will mark Pharmaceutical Technology’s 35th anniversary, and as part of a special issue to be published in July 2012, we are seeking to gain your input on what you feel have been the most noteworthy achievements in the pharmaceutical sciences and manufacturing and what future developments may shape the industry. Read more »

Could Ben Venue’s Manufacturing Suspension Have Been Avoided?

Erik Greb PharmTech editorWhen only a handful of manufacturers supply a given drug, production problems at any of those companies can lead to a shortage. Earlier this year, problems at Ben Venue’s Bedford, Ohio, site contributed to shortages of the cancer drug Doxil. The shortages are likely to continue now that Ben Venue has suspended manufacturing at the plant. Read more »

Tax Breaks for Big Pharma: A Remedy for Unemployment?

Erik Greb PharmTech editorWorried about our persistently high rate of unemployment (and his bid for re-election), President Obama is urging Congress to pass portions of his jobs bill. In addition to aiding the economy, creating jobs could help reduce the number of people who are forgoing medications, which would be a boon for the pharmaceutical industry. Perhaps with this in mind, the Association of Clinical Research Organizations (ACRO) has thrown its weight behind a bill it says would create American jobs.

Read more »

Changing Times for Pharma Chemical Outsourcing

Patricia Van Arnum PharmTech editor The Pharma ChemOutsourcing conference, an annual event that brings together pharmaceutical companies, CROs, and CMOs to discuss industry trends and perspectives, was held in Long Branch, New Jersey, last week. The central question at the heart of many of the discussions was a fundamental but important one: where is the opportunity in pharmaceutical outsourcing, specifically in pharmaceutical chemical development and manufacturing? Read more »

Senator Mikulski on Supply Chain and National Security

As blogged earlier this week, the Senate Healthcare, Education, Labor, and Pensions committee met this week to discuss the pharma supply chain and Senator Barbara Mikulski (D-MD) had some interesting comments about making supply chain concerns a national security issue. Below are highlights from her remarks, including a Q&A portion with FDA’s Deborah Autor, as sent to PharmTech by the Senator’s press office.

Read more »

Data on Offshore Manufacturing

Amy RitterOver 80% of APIs are now sourced from counties outside of the US, including from developing countries. As such, drug quality has become more difficult to control. Drug manufacturing plants in the US, owned by US-based manufacturers, are sometimes plagued by quality concerns. Yet, because of the highly-regulated environment and the transparency with which US and European firms operate, consumers have high expectations of quality from products manufactured in the US and Europe. Quantifying the risks associated with offshore manufacturing, and identifying its causes are important steps in controlling the quality of drugs that come from widely-dispersed facilities. Read more »

Woodcock Cites a “Turning Point” in Drug Development

Erik Greb PharmTech editor

Some drugmakers have blamed what they see as a slow and overly cautious FDA for the industry’s weak pipelines. Last week, I cited drug-approval figures to show that the agency was not standing in the way of innovation. A closer look at the figures contradicts another part of the critics’ argument—the industry’s pipelines may not be so weak after all. Read more »

« Previous PageNext Page »